Enabling Unbiased Container Selection: Large-Volume IV & SC Drug Delivery Solutions

As biologics progress along their lifecycle, the transition from vial-based formats to advanced pre-filled systems becomes critical to enable patient-centric delivery and lifecycle value optimization. As the shift from intravenous to subcutaneous delivery accelerates, large-volume subcutaneous (LVSC) biologics are redefining requirements for primary packaging. Enabling volumes beyond traditional limits demands solutions that ensure drug stability, patient safety, and seamless device integration. SCHOTT Pharma addresses this need with advanced, ready-to-use (RTU) platform innovations, expanding both glass and polymer portfolios across syringes and cartridges.

Designed for sensitive biologics and high-viscosity formulations, they combine low extractables, optimized silicone technology, and high break resistance with tight tolerances. Co-developed with leading device partners and aligned with standard fill-and-finish line requirements, these next-generation systems give pharmaceutical companies a decisive competitive edge - minimizing development risk, accelerating time-to-market, and enabling reliable scale-up of LVSC therapies.